Teva Pharmaceutical Industries Limited (TEVA)

12.95 +0.17 (+1.33%) As of 10:44AM EDT. Market open.

Teva Pharmaceutical Industries Limited

124 Dvora HaNevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 35,001

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Eric Drape	Executive Vice President of Global Operations	1.91M	N/A	1962
Mr. Mark Sabag	Executive Vice President of International Markets Commercial	1.92M	N/A	1971
Mr. Richard D. Francis	President, CEO & Director	N/A	N/A	1968
Mr. Amir Weiss	Senior VP & Chief Accounting Officer	N/A	N/A	1977
Ran Meir	Head of Investor Relations	N/A	N/A	N/A
Mr. Kevin C. Mannix	Senior Vice President of Investor Relations	N/A	N/A	N/A
Advocate Nir Baron	Senior VP & Chief Internal Auditor	N/A	N/A	N/A
Mr. Richard Gordon Daniell	Executive Vice President of European Commercial	N/A	N/A	1967
Mr. John Nason	President of Teva Active Pharmaceutical Ingredients (TAPI) & Biologics Operations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Corporate governance

Teva Pharmaceutical Industries Limited’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.